Sotatercept in Patients With MPN-Associated Myelofibrosis and Anemia

Solly Chedid, MD, discussed luspatercept and its role in boosting quality of life for patients with myelodysplastic syndrome.

The FDA granted fast track designation to NX-5948 for treating relapsed/refractory Waldenström macroglobulinemia after 2 or more lines of therapy, including a BTK inhibitor.

Frontline tyrosine kinase inhibitors are well-established for chronic myelogenous leukemia, but some patients experience inadequate response or adverse events, highlighting the need for novel therapies.

Positive topline data from a phase 2 trial show HT-6184, an allosteric NEK7/NLRP3 inflammasome inhibitor, improves hematologic response in lower-risk MDS.

Here are some of the highlights from this year's 2024 ASH Annual Meeting & Exposition.

Memorial Sloan Kettering Cancer Center physicians describe challenges in diagnosis, patient care, and the potential expansion of telehealth in this continuation of November's coverfeature.